Intra-cellular therapies reports third quarter 2021 financial results and provides corporate update

Caplyta supplemental new drug applications (sndas) for the treatment of bipolar depression are under review by the fda, with a pdufa target action date of december 17, 2021.

ITCI Ratings Summary

ITCI Quant Ranking